Several radioisotopes of iodine (I, I, I, and I) are available for medical use. One of them can be used, depending on the application, for radioiodine labeling of New Chemical Entities (NCEs) and biomolecules (peptides, proteins, protein fragments, monoclonal antibodies, etc.) for the development of novel imaging and therapeutic pharmaceuticals. Direct, using inorganic and organic oxidizing agents and enzyme catalysts, and indirect, using prosthetic groups, radioiodine-labeling methods have been used routinely in the past. In this report, a comprehensive review of the physical properties of various iodine radionuclides, their medical applications, and a summary of various radioiodine labeling reagents and methods for NCEs and biomolecules are provided.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/cbr.2021.0233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.
Lancet Diabetes Endocrinol
January 2025
Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France.
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (I) administration compared with a postoperative I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up.
Methods: Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone).
Development of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity.
Mol Pharm
January 2025
Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Article Synopsis
- Radioiodine is used in nuclear medicine for diagnosing and treating diseases, primarily through two methods of radioiodination: direct and indirect.
- The newly developed compound 3-[I]IBTTT offers a high radiochemical yield and purity while simplifying purification processes, overcoming issues present in traditional methods.
- This compound demonstrated effective HER2-specific binding in tumor imaging with minimal thyroid uptake, making it a promising option for targeting HER2-positive cancers.
Direct Labeling of Gold Nanoparticles with Iodine-131 for Tumor Radionuclide Therapy.
Int J Nanomedicine
November 2024
Department of Nuclear Medicine, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China.
Article Synopsis
- Gold nanoparticles (Au NPs) can be easily labeled with radioactive iodine, making them promising tools for tumor treatment and diagnosis in cancer therapy.
- This study evaluated the stability and effectiveness of iodine-adsorbed Au NPs in targeting tumors, using various conditions to analyze their performance.
- The results indicate that these iodine-adsorbed Au NPs are stable, effective in inhibiting tumor cells, and show therapeutic potential when injected into tumors in living subjects.
TSH Stimulation before PET/CT as Our Frenemy in Detecting Thyroid Cancer Metastases-Final Results of a Retrospective Analysis.
Cancers (Basel)
October 2024
Department of Endocrinology and Isotope Therapy, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Non-iodine avid metastases of differentiated thyroid cancer (DTC) can be found using PET/CT with a fluorine-18-labeled glucose analog ([F]FDG). There are ongoing discussions on the appropriateness of using exogenous thyrotropin (TSH) stimulation before this examination. In a retrospective study, 73 PET/CT scans with [F]FDG performed after exogenous stimulation with recombinant human TSH (rhTSH) and without such stimulation were analyzed.
View Article and Find Full Text PDFInvestigation of a Radio-Iodinated Alpha-Mangostin for Targeting Estrogen Receptor Alpha (ERα) in Breast Cancer: In Silico Design, Synthesis, and Biological Evaluation.
Drug Des Devel Ther
October 2024
Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, Japan.
Article Synopsis
- Alpha-mangostin (AM), derived from the Purple Mangosteen, shows potential in breast cancer treatment and is believed to interact with the estrogen receptor alpha (ERα), but no direct binding studies had been conducted until this research.* -
- This study used iodine-125 labeled AM to explore its binding to ERα in lab-grown breast cancer cells (MCF-7) and demonstrated that AM and tamoxifen can inhibit its uptake, indicating that AM's uptake involves ERα.* -
- The injected labeled AM was found to accumulate in tumors in mice, but some of the iodine-125 was lost during the process, highlighting the need for further research to improve retention and effectiveness as a breast cancer treatment
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!